Oral insulin reduces liver fat

Israel’s Oramed (see here previously) has reported that its ORMD-0801 oral insulin candidate successfully reduced the liver fat in its Phase 2 trial on Type 2 diabetes patients with non-alcoholic steatohepatitis (“NASH”).  There were no safety issues in the double-blind, multi-center trial.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *